Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Cardiovascular Imaging
Can coronary CTA provide any additional information on the characteristics of a calcified plaque, and would FFR assessment be accurate in predicting the degree of stenosis?
Related Questions
What is a reasonable surveillance strategy in terms of preferred imaging modality and frequency of monitoring for suspected AV bioprosthetic stenosis in patients status post SAVR?
For asymptomatic, incidentally found Lambl's excrescence, should long-term surveillance imaging be considered and if so, how often should repeat imaging be ordered?
For a patient with prior bypass graft stenting and severe native vessel disease, would you recommend myocardial perfusion imaging or coronary CTA if there is concern about graft patency?
What is the clinical significance of intracardiac vacuum(s) noted during diastole, especially in terms of the diagnosis and management of diastolic dysfunction?
How do you distinguish between senile/hypertensive sigmoid septal hypertrophy versus sigmoid septal hypertrophy seen in hypertrophic cardiomyopathy?
Would you recommend hospitalization for surgery for a large papillary fibroelastoma or atrial myxoma discovered on an outpatient echocardiogram?
What is a reasonable approach to coronary calcification that is incidentally found on CT in a patient who does not have symptoms suggestive of angina?
What is the best way to categorize aortic stenosis in normal LV function with normal LV size, when the peak velocity and mean pressure gradient are in moderate range but AVA shows severe?
What are some TTE findings that suggest worsening function of a bioprosthetic AVR that would require further surveillance or diagnostic imaging?
What is your preferred imaging modality--cMR vs. TTE--to evaluate for myocardial strain if concerned for chemotherapy-induced cardiomyopathies?
